MX381590B - Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico. - Google Patents

Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico.

Info

Publication number
MX381590B
MX381590B MX2019003093A MX2019003093A MX381590B MX 381590 B MX381590 B MX 381590B MX 2019003093 A MX2019003093 A MX 2019003093A MX 2019003093 A MX2019003093 A MX 2019003093A MX 381590 B MX381590 B MX 381590B
Authority
MX
Mexico
Prior art keywords
crystalline forms
pharmaceutical compositions
phosphonopropionyl
pyrrolidine
piperazine
Prior art date
Application number
MX2019003093A
Other languages
English (en)
Spanish (es)
Other versions
MX2019003093A (es
Inventor
Daniel Leuenberger
Raumer Markus Von
Stefan Reber
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2019003093A publication Critical patent/MX2019003093A/es
Publication of MX381590B publication Critical patent/MX381590B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2019003093A 2016-09-22 2017-09-21 Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico. MX381590B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (2)

Publication Number Publication Date
MX2019003093A MX2019003093A (es) 2019-07-18
MX381590B true MX381590B (es) 2025-03-12

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003093A MX381590B (es) 2016-09-22 2017-09-21 Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico.

Country Status (27)

Country Link
US (4) US10730896B2 (OSRAM)
EP (2) EP3515924B1 (OSRAM)
JP (1) JP7097369B2 (OSRAM)
KR (1) KR102552795B1 (OSRAM)
CN (1) CN109715639B (OSRAM)
AU (1) AU2017331930B2 (OSRAM)
CA (1) CA3037794A1 (OSRAM)
CL (1) CL2019000728A1 (OSRAM)
CY (1) CY1125052T1 (OSRAM)
DK (1) DK3515924T3 (OSRAM)
EA (1) EA201990723A1 (OSRAM)
ES (1) ES2908572T3 (OSRAM)
HR (1) HRP20220234T1 (OSRAM)
HU (1) HUE057772T2 (OSRAM)
IL (1) IL265445B2 (OSRAM)
LT (1) LT3515924T (OSRAM)
MA (1) MA46266B1 (OSRAM)
MX (1) MX381590B (OSRAM)
MY (1) MY193080A (OSRAM)
PH (1) PH12019500567B1 (OSRAM)
PL (1) PL3515924T3 (OSRAM)
PT (1) PT3515924T (OSRAM)
RS (1) RS62946B1 (OSRAM)
SI (1) SI3515924T1 (OSRAM)
TW (1) TWI752086B (OSRAM)
UA (1) UA124073C2 (OSRAM)
WO (1) WO2018055016A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3515924T (pt) 2016-09-22 2022-03-11 Idorsia Pharmaceuticals Ltd Formas cristalinas
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
EP4181872B1 (en) 2020-07-15 2025-11-26 Viatris Asia Pacific Pte. Ltd. Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist
MX2024000653A (es) 2021-07-13 2024-01-31 Idorsia Pharmaceuticals Ltd Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
DE60022508T2 (de) 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
ES2348942T3 (es) 2002-12-11 2010-12-17 Bayer Schering Pharma Aktiengesellschaft Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor plaquetario de adenosin difosfato.
CA2521313A1 (en) 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.o)non-1(7)-3n-2-yl)-al kyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
WO2007046075A1 (en) 2005-10-21 2007-04-26 Actelion Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MX2009011089A (es) 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
CN101868469B (zh) 2007-11-29 2014-04-02 埃科特莱茵药品有限公司 膦酸衍生物及其作为p2y12受体拮抗剂
WO2009080227A2 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
WO2009080226A2 (en) 2007-12-26 2009-07-02 Sanofis-Aventis Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
SG175297A1 (en) 2009-04-22 2011-12-29 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
PT3515924T (pt) 2016-09-22 2022-03-11 Idorsia Pharmaceuticals Ltd Formas cristalinas
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
EP4181872B1 (en) 2020-07-15 2025-11-26 Viatris Asia Pacific Pte. Ltd. Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist

Also Published As

Publication number Publication date
WO2018055016A1 (en) 2018-03-29
DK3515924T3 (da) 2022-03-21
US11365209B2 (en) 2022-06-21
MA46266B1 (fr) 2022-02-28
JP2019529553A (ja) 2019-10-17
RS62946B1 (sr) 2022-03-31
TW201813965A (zh) 2018-04-16
HRP20220234T1 (hr) 2022-05-13
KR102552795B1 (ko) 2023-07-06
IL265445A (en) 2019-05-30
PH12019500567B1 (en) 2024-01-31
MY193080A (en) 2022-09-26
EP3515924A1 (en) 2019-07-31
US20220275011A1 (en) 2022-09-01
EP3515924B1 (en) 2021-12-15
BR112019004845A2 (pt) 2019-06-04
AU2017331930B2 (en) 2021-07-15
CA3037794A1 (en) 2018-03-29
TWI752086B (zh) 2022-01-11
CY1125052T1 (el) 2024-02-16
US12227532B2 (en) 2025-02-18
PT3515924T (pt) 2022-03-11
MX2019003093A (es) 2019-07-18
AU2017331930A1 (en) 2019-03-07
HUE057772T2 (hu) 2022-06-28
CL2019000728A1 (es) 2019-07-05
SI3515924T1 (sl) 2022-04-29
EP3981774A1 (en) 2022-04-13
US20250163086A1 (en) 2025-05-22
UA124073C2 (uk) 2021-07-14
US10730896B2 (en) 2020-08-04
NZ750772A (en) 2023-10-27
MA46266A (fr) 2019-07-31
US20210009614A1 (en) 2021-01-14
US20200017534A1 (en) 2020-01-16
IL265445B2 (en) 2024-05-01
LT3515924T (lt) 2022-03-10
PL3515924T3 (pl) 2022-04-11
JP7097369B2 (ja) 2022-07-07
IL265445B1 (en) 2024-01-01
CN109715639A (zh) 2019-05-03
KR20190052704A (ko) 2019-05-16
EA201990723A1 (ru) 2019-10-31
ES2908572T3 (es) 2022-05-03
CN109715639B (zh) 2022-04-19
PH12019500567A1 (en) 2019-11-18

Similar Documents

Publication Publication Date Title
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
CL2017002650A1 (es) Compuestos novedosos
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2016001895A1 (es) Compuestos
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX381590B (es) Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico.
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
BR112017009852A2 (pt) composto, composição, e, usos de um composto